Premium
Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers
Author(s) -
Hua Teng C.,
Pan Alan,
Chan Clark,
Poo Yeo K.,
Skinner Michael H.,
Knadler Mary P.,
Gonzales Celedon R.,
Wise Stephen D.
Publication year - 2004
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2004.02068.x
Subject(s) - tolterodine , duloxetine , pharmacokinetics , duloxetine hydrochloride , tolerability , placebo , medicine , crossover study , pharmacology , population , adverse effect , urology , anesthesia , overactive bladder , alternative medicine , environmental health , pathology
Aim To investigate the effect of duloxetine on the pharmacokinetics and tolerability of tolterodine and its active 5‐hydroxymethyl metabolite (5‐HM). Methods Sixteen healthy subjects received two 5‐day treatment regimens in a randomized, double‐blinded, crossover fashion: tolterodine (2 mg, BID) + duloxetine (40 mg, BID), tolterodine (2 mg, BID) + duloxetine placebo (BID). Plasma concentrations of tolterodine and 5‐HM were measured on day 5. Adverse events, clinical safety laboratory data and vital signs were assessed during the study. Results Duloxetine increased the AUC τ,ss of tolterodine by 71%[geometric mean, 95% confidence interval (CI) 31, 123], and its C max,ss by 64% (CI 30, 106), and prolonged its t 1/2 by 14% (CI 1, 28). Duloxetine did not affect the plasma concentrations or t 1/2 of 5‐HM. Laboratory data and vital signs did not reveal any clinically significant changes or abnormalities. Conclusions Duloxetine exhibited minor inhibitory effects on the pharmacokinetics of tolterodine but not 5‐HM. Coadministration of these drugs was well tolerated and demonstrated no significant safety findings in the studied population. These findings suggest that there should not be a need for routine adjustment of tolterodine dosage in the presence of duloxetine.